SENIOR LEADERSHIP

高层领导

基本信息

项目摘要

Senior Leadership are individuals with the requisite skill sets that in their totality, provide a balanced and complete perspective on our Cancer Center to ensure its optimal growth, function, resource utilization, and intra- and inter-programmatic interactions. These individuals also represent relevant aspects of Cancer Center affairs to the various clinical and research entities that comprise our matrix environment to ensure that the Cancer Center interacts to best advantage and can best capitalize on available external resources. Leadership includes the Cancer Center Executive Director (Dr. Curiel) and Deputy Director (Dr. Giles), our three scientific Associate Directors, Dr. Slaga (Basic and Translational Research), Dr. Naylor (Shared Resources and Internal Education) and Dr. Pollock (Cancer Prevention and Control). Dr. Ramirez serves as Senior Leadership owing to her directorship of the Institute for Health Promotion Research, which serves a critical cancer prevention and Hispanic outreach function for our Cancer Center. We also have an interim Associate Director of Administration with greatly augmented authority and a clear Senior Leadership role as requested in the prior review. A national search for a permanent Associate Director of Administration is undenway, with the expectation that the permanent position will be filled by the time of the site visit. The Senior Leadership ensures that our Cancer Center discharges its public trust through appropriate stewardship of NCI, NIH and related, institutional and philanthropic dollars to translate discoveries into practical applications that provide for the clinical and research cancer care needs of San Antonio, South Texas and the nation. All Senior Leadership members sit on the Executive Committee and other important committees that set current Cancer Center agendas, plan for future growth, challenges and opportunities and help set budgets, recruiting pnorities and scientific agendas that meet these various needs. Support is requested for Dr. Curiel (50%), Dr. Giles (5%), Dr. Naylor (10%), Dr. Ramirez (10%), Dr. Slaga (20%), and Ms. McCarroll (50%). Some Senior Leadership also serve as Program Leaders, but generally those duties are co-shared with Senior Leadership in terms of financial support. Thus, most support for the totality'of the efforts of these individuals comes from Senior Leadership, freeing our scare resources in the budget for additional, constructive uses in our Cancer Center.
高级领导是具有必要技能的个人,这些技能总体上提供了一个平衡的, 全面了解我们的癌症中心,以确保其最佳增长,功能,资源利用, 方案内和方案间的互动。这些人也代表了癌症的相关方面 中心事务,以各种临床和研究实体,构成我们的矩阵环境,以确保 确保癌症中心的互动能够发挥最大的优势,并能够最好地利用现有的外部资源。 领导层包括癌症中心执行主任(Curiel博士)和副主任(Giles博士),我们的 三位科学副主任,Slaga博士(基础和转化研究),Naylor博士(共享 资源和内部教育)和波洛克博士(癌症预防和控制)。拉米雷斯博士担任 由于她担任健康促进研究所所长,担任高级领导职务,该研究所为一个 重要的癌症预防和西班牙裔外展功能为我们的癌症中心。我们还有一个临时 协理行政主任的权力大大增加,并具有明确的高级领导作用, 在审查前要求。在全国范围内寻找一名永久的行政助理主任, undenway,预计到实地考察时,该长期职位将得到填补。的 高级领导层确保我们的癌症中心通过适当的方式履行其公众信任 管理NCI、NIH和相关机构和慈善机构的资金,将发现转化为 提供临床和研究癌症护理需求的实际应用,南圣安东尼奥 德州和国家所有高级领导成员都是执行委员会成员, 制定当前癌症中心议程的委员会,计划未来的发展,挑战和机遇 并帮助制定预算,招募人才和满足这些不同需求的科学议程。支持是 Curiel博士(50%),Giles博士(5%),Naylor博士(10%),Ramirez博士(10%),Slaga博士(20%), 女士McCarroll(50%)。一些高级领导也担任项目负责人,但通常这些职责 在财政支持方面与高级领导共同分担。因此,大多数人都支持“整体”, 这些人的努力来自高级领导层,释放了我们预算中的稀缺资源, 在我们的癌症中心有额外的建设性用途。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tyler J. Curiel其他文献

ESTABLISHMENT OF A DOUBLE-HUMANIZED MOUSE MODEL USING PATIENT-DERIVED XENOGRAFT BLADDER CANCER TUMOR CELL LINE AND HUMAN γδ T-CELLS
  • DOI:
    10.1016/j.urolonc.2024.01.171
  • 发表时间:
    2024-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Shaun Trecarten;Robert S. Svatek;Niannian Ji;Zhen-Ju Shu;Tyler J. Curiel;Neelam Mukherjee;Jamie Furman
  • 通讯作者:
    Jamie Furman
PD48-06 2 YEAR CLINICAL AND IMMUNOLOGIC OUTCOMES OF INTRADERMAL BCG PRIMING PRIOR TO INTRAVESICAL INDUCTION IMMUNOTHERAPY FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER
  • DOI:
    10.1016/j.juro.2017.02.2354
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Niannan Ji;Edwin E. Morales;Neelam Mukherjee;Vincent Hurez;Tyler J. Curiel;Getahun Abate;Daniel F. Hoft;Robert S. Svatek
  • 通讯作者:
    Robert S. Svatek
60: Oral rapamycin prevents carcinogen-induced dermal carcinogenesis through immune mechanisms
  • DOI:
    10.1016/j.cyto.2013.06.063
  • 发表时间:
    2013-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Vinh Dao;Vincent Hurez;Sri Lakshmi Pandeswara;Lishi Sun;Aijie Liu;Paul Hasty;Dave Sharp;Tyler J. Curiel
  • 通讯作者:
    Tyler J. Curiel

Tyler J. Curiel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tyler J. Curiel', 18)}}的其他基金

Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
膀胱癌 PD-L1 对同源重组的控制:应用于新疗法的基本机制
  • 批准号:
    10467877
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
膀胱癌 PD-L1 对同源重组的控制:应用于新疗法的基本机制
  • 批准号:
    10688261
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
Regulation of ER-beta Signaling in Carcinogenesis
ER-β 信号传导在癌发生过程中的调节
  • 批准号:
    10092967
  • 财政年份:
    2019
  • 资助金额:
    $ 7.5万
  • 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
  • 批准号:
    9788318
  • 财政年份:
    2018
  • 资助金额:
    $ 7.5万
  • 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
  • 批准号:
    10381324
  • 财政年份:
    2018
  • 资助金额:
    $ 7.5万
  • 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
  • 批准号:
    10475260
  • 财政年份:
    2018
  • 资助金额:
    $ 7.5万
  • 项目类别:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
(PQ2) 接受癌症免疫治疗的老年宿主体内的 PD-L1/PD-1 信号
  • 批准号:
    10247570
  • 财政年份:
    2018
  • 资助金额:
    $ 7.5万
  • 项目类别:
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
(PQ
  • 批准号:
    9926828
  • 财政年份:
    2017
  • 资助金额:
    $ 7.5万
  • 项目类别:
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
(PQ
  • 批准号:
    9307468
  • 财政年份:
    2017
  • 资助金额:
    $ 7.5万
  • 项目类别:
Immune aspects of mTOR inhibition for cancer prevention (PQ5)
mTOR 抑制的免疫方面预防癌症 (PQ5)
  • 批准号:
    8538910
  • 财政年份:
    2012
  • 资助金额:
    $ 7.5万
  • 项目类别:

相似海外基金

Can megafauna shift the carbon and surface radiation budgets of the Arctic?
巨型动物群能否改变北极的碳和地表辐射预算?
  • 批准号:
    NE/W00089X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Research Grant
Resilience of pollinators in a changing world: impact of developmental environment on metabolism and energetic budgets in social and solitary bees
不断变化的世界中授粉媒介的复原力:发育环境对群居和独居蜜蜂新陈代谢和能量预算的影响
  • 批准号:
    BB/X016641/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Research Grant
An innovative EDI data, insights & peer benchmarking platform enabling global business leaders to build data-led EDI strategies, plans and budgets.
创新的 EDI 数据、见解
  • 批准号:
    10100319
  • 财政年份:
    2024
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Collaborative R&D
Nutrient budgets as a tool for minimizing nitrogen and phosphorus losses from agricultural fields
养分预算作为最大限度减少农田氮磷损失的工具
  • 批准号:
    574867-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    University Undergraduate Student Research Awards
Collaborative Research: ORCC: The role of bioenergetic budgets in defining elevation limits and modeling geographic ranges of species
合作研究:ORCC:生物能预算在定义海拔限制和建模物种地理范围中的作用
  • 批准号:
    2222475
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Standard Grant
Collaborative Research: ORCC: The role of bioenergetic budgets in defining elevation limits and modeling geographic ranges of species
合作研究:ORCC:生物能预算在定义海拔限制和建模物种地理范围中的作用
  • 批准号:
    2222476
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Continuing Grant
CNS Core: Small: Budgets, Budgets Everywhere: A Necessity for Safe Real-Time on Multicore
CNS 核心:小:预算,预算无处不在:多核安全实时的必要性
  • 批准号:
    2151829
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Standard Grant
Sea-ice Snow Microbial Communities’ Impact on Antarctic Bromocarbon Budgets and Processes
海冰雪微生物群落对南极溴碳预算和过程的影响
  • 批准号:
    2031121
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Standard Grant
Breathing streams: integrating aquatic emissions into carbon budgets
呼吸流:将水生排放纳入碳预算
  • 批准号:
    DE220100852
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Discovery Early Career Researcher Award
Can megafauna shift the carbon and surface radiation budgets of the Arctic?
巨型动物群能否改变北极的碳和地表辐射预算?
  • 批准号:
    NE/W00089X/1
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了